Document Detail


Pharmacologic support in cardiogenic shock.
MedLine Citation:
PMID:  6349299     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Cardiogenic shock is a relatively specific clinical syndrome characterized by decreased cardiac output, elevated left ventricular filling pressure, and arterial hypotension with vital organ hypoperfusion. It most commonly occurs as the consequence of extensive left ventricular damage due to myocardial infarction. The prognosis of patients with cardiogenic shock is very poor, because by definition there are no readily correctable metabolic, hemodynamic, humoral, or infectious problems whose treatment may lead to improved circulatory function. Pharmacologic support of the patient with cardiogenic shock plays a major role in clinical management. Diuretics, inotropic agents, and vasodilator drugs all have a place in the management of selected patients with low output states and cardiogenic shock following myocardial infarction. Diuretics such as furosemide may be used to relieve symptoms of pulmonary congestion, but are not effective in reversing hypotension or vital organ hypoperfusion; in advanced shock states with acute renal failure, they may be totally ineffective. The most commonly employed and effective inotropic agents are the sympathomimetic amines dopamine and dobutamine, which have complex effects on important variables in cardiogenic shock, including the heart's inotropic and chronotropic states, myocardial oxygen requirements, left ventricular filling pressure, and peripheral vascular tone. All inotropic agents have the capacity to intensify myocardial ischemia because they may increase myocardial oxygen requirements in the face of limited arterial blood flow; isoproterenol, epinephrine, and norepinephrine appear to be particularly troublesome in this regard. Vasodilator agents (phentolamine, nitroprusside, and nitroglycerin) have also been used to alter left ventricular loading conditions in patients otherwise supported by inotropic drugs, and may be particularly useful in the management of "mechanical" complications of infarction such as mitral regurgitation and interventricular septal rupture. The use of these drugs, just as that of inotropic agents, must be tailored to specific hemodynamic abnormalities documented in individual patients.
Authors:
R E Rude
Related Documents :
20185109 - Differences in effects of electrical therapy type for ventricular arrhythmias on mortal...
19468019 - Intractable cardiogenic shock in stress cardiomyopathy with left ventricular outflow tr...
19092649 - Cardiovascular manifestations of sedatives and analgesics in the critical care unit.
9249849 - Alternating current electrocution detection and termination by an implantable cardiover...
8575009 - Myocardial gi alpha-protein levels in patients with hypertensive cardiac hypertrophy, i...
16327039 - Four days of percutaneous cardiopulmonary support and sixteen days of percutaneous left...
17532519 - Gelatin microspheres encapsulated with a nonpeptide angiogenic agent, ginsenoside rg1, ...
24426869 - First time myocardial infarction in a rheumatic patient after elective arthroplasty.
12829859 - Leukoaraiosis: an independent risk factor for stroke?
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review    
Journal Detail:
Title:  Advances in shock research     Volume:  10     ISSN:  0195-878X     ISO Abbreviation:  Adv Shock Res     Publication Date:  1983  
Date Detail:
Created Date:  1983-09-09     Completed Date:  1983-09-09     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  7908298     Medline TA:  Adv Shock Res     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  35-49     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Cardiotonic Agents / administration & dosage
Diagnosis, Differential
Digitalis Glycosides / administration & dosage
Diuretics / administration & dosage
Dobutamine / administration & dosage
Dopamine / administration & dosage
Humans
Isoproterenol / administration & dosage
Monitoring, Physiologic
Myocardial Infarction / complications*,  drug therapy,  therapy
Norepinephrine / administration & dosage
Shock, Cardiogenic / diagnosis,  drug therapy*,  etiology
Syndrome
Vasodilator Agents / administration & dosage
Grant Support
ID/Acronym/Agency:
1-K08-HL0882-01/HL/NHLBI NIH HHS; HL-17669/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Cardiotonic Agents; 0/Digitalis Glycosides; 0/Diuretics; 0/Vasodilator Agents; 34368-04-2/Dobutamine; 51-41-2/Norepinephrine; 7683-59-2/Isoproterenol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prevention or amelioration of morphologic lesions in LD100 E coli-shocked baboons with steroid/antib...
Next Document:  The pathophysiology of septic shock: responses to different doses of live Escherichia coli injection...